文献速递糖尿病

美国国立糖尿病、消化和肾脏疾病研究所致力于解决1型糖尿病并发症:糖尿病控制与并发症试验/糖尿病干预与并发症流行病学研究(DCCT/EDIC)

The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
PubMed 文献 · Diabetes Care · 2025-01-01

糖尿病控制与并发症试验(DCCT,1983-1993)在1,441例青少年和成人1型糖尿病患者中比较强化治疗与传统治疗,平均随访6.5年,强化治疗(平均HbA1c约7%)较传统治疗(HbA1c约9%)使微血管并发症发生和进展风险降低35%-76%。随后的糖尿病干预与并发症流行病学研究(EDIC,1994年至今)作为观察性随访显示,强化治疗的早期获益在两组HbA1c水平趋同后仍持续约10年,称为「代谢记忆」。

要点

  • DCCT显示强化治疗(平均HbA1c约7%)较传统治疗(HbA1c约9%)使微血管并发症风险降低35%-76%。
  • EDIC显示强化治疗获益在HbA1c趋同后持续约10年,称为「代谢记忆」。
  • DCCT/EDIC队列随访覆盖95%的糖尿病病程和65%的生命周期,是研究最广泛的1型糖尿病队列。

核心结论

  • DCCT/EDIC 40余年的结果指导了1型糖尿病的治疗优先事项,改善了全球数百万1型糖尿病患者的生存和生活质量。

研究设计与样本

  • DCCT(1983-1993)在1,441例青少年和成人1型糖尿病患者中比较强化治疗(目标接近血糖正常)与传统治疗,平均随访6.5年。
  • EDIC(1994年至今)为DCCT队列的观察性随访研究。

主要发现

  • DCCT显示强化治疗(平均HbA1c约7%)较传统治疗(HbA1c约9%)使微血管并发症发生和进展风险降低35%-76%。
  • EDIC显示强化治疗对并发症的早期获益在两组HbA1c水平趋同后仍持续约10年,称为「代谢记忆」。
  • EDIC显示既往强化治疗还降低严重微血管并发症、心血管疾病、死亡以及认知障碍、骨丢失和活动能力下降等年龄相关结局的风险。

关键数值与推荐

  • HbA1c <7%被全球采纳为1型糖尿病的治疗目标。

临床怎么用

  • DCCT/EDIC的结果指导了1型糖尿病的治疗优先事项。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the Diabetes Control and Complications Trial (DCCT) (1983-1993), intensive therapy aimed at near-normal glycemia was compared with conventional therapy in 1,441 adolescent and adult participants with type 1 diabetes (T1D) over a mean follow-up of 6.5 years. The primary DCCT results, reported in 1993, demonstrated the benefits of intensive therapy (mean HbA1c ∼7%) compared with conventional therapy (HbA1c ∼9%) in reducing the risk of development and progression of microvascular complications by 35%-76%. HbA1c <7% was adopted worldwide as the therapeutic target for T1D. Subsequently, the Epidemiology of Diabetes Interventions and Complications (EDIC) study (1994-present) was initiated as the observational follow-up of the DCCT cohort. EDIC has shown that the early beneficial effects of intensive versus conventional therapy on complications persisted for ∼10 years after the convergence of HbA1c levels in the two groups during EDIC-a novel concept termed "metabolic memory." During EDIC, prior intensive therapy was also shown to reduce the risk of severe microvascular complications, cardiovascular disease, mortality, and, recently, of age-related outcomes including cognitive impairment, bone loss, and reduced mobility. The DCCT/EDIC cohort is the most extensively studied T1D cohort in history. The participants have been followed and deeply phenotyped for 95% of their diabetes durations and 65% of their lifespans. Throughout its 40+ years, funded by and in close collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases, DCCT/EDIC has generated results that have guided treatment priorities in T1D and led to improved survival and quality of life for millions of people with T1D worldwide.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Braffett BH, Bebu I, Lorenzi GM, et al. The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2025. PMID: 40272271. doi:10.2337/dc24-2885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。